治疗缺铁 (ID) 贫血心力衰竭 (HF) 患者的IV铁:一个元分析
Fredrick M Ogugua1, Francisco A Aguilar2, Abdulrahman Gamam3
1Cardiology, University of Illinois Chicago, Chicago, USA.
Cureus
|August 15, 2023
概括
静脉注射铁疗法显著减少了铁缺乏症患者的心力衰竭住院的情况. 然而,尽管改善了关键健康指标,这种治疗并没有显著影响全因死亡率.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 内部医学 内部医学
背景情况:
- 关于铁对心力衰竭 (HF) 住院和铁缺乏症 (ID) 患者死亡率的影响存在相互矛盾的发现.
- 缺铁是心力衰竭患者常见的并发症,影响他们的临床结果.
- 了解这些人群中补充铁的好处对于优化治疗策略至关重要.
研究的目的:
- 进行一项元分析,评估治疗心力衰竭患者缺铁症的临床,血液和心血管益处.
- 评估静脉注射 (IV) 铁疗法对心力衰竭住院和全因死亡率的影响.
- 检查二次结果,包括血液值,纽约心脏协会 (NYHA) 课程和射出分数.
主要方法:
- 系统搜索临床试验,比较IV铁与安慰剂在ID的HF患者.
- 使用随机效应模型进行元分析.
- 包括9项研究,共2261名患者;进行了敏感性分析.
主要成果:
- 静脉铁替代剂显著降低了HF住院的几率 (OR:0.44;95%CI:0.24至0.78).
- 没有观察到对所有原因死亡率的显著影响 (OR:0.89;95% CI:0.67至1.19).
- 静脉铁治疗导致血清费里,转林和度,血红蛋白水平显著改善,NYHA类减少,喷射分数增加.
结论:
- 在患有ID的HF患者中,用IV铁治疗与HF住院病例的显著减少有关.
- 在这个患者群体中,静脉铁疗法没有显著影响全因死亡率.
- 血液值,射出分数和NYHA类的显著改善被观察到,这表明临床益处.
更多相关视频
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:30Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:30Heart Failure VII: Nursing Interventions
94
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
94
01:26Heart Failure III: Clinical Manifestations
23
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
23
01:26Heart Failure Drugs: Inotropic Agents
622
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
622